Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.1700
-0.0001 (-0.06%)
At close: Aug 31, 2026, 4:00 PM EDT
0.1708
+0.0008 (0.47%)
After-hours: Aug 31, 2026, 7:59 PM EDT
Gossamer Bio Employees
As of December 31, 2025, Gossamer Bio had 162 total employees, including 161 full-time and 1 part-time employees. The number of employees increased by 17 or 11.72% compared to the previous year.
Employees
162
Change (1Y)
17
Growth (1Y)
11.72%
Revenue / Employee
$328,926
Profits / Employee
-$772,981
Market Cap
83.10M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 162 | 17 | 11.72% | 161 | 1 |
| Dec 31, 2024 | 145 | 10 | 7.41% | 144 | 1 |
| Dec 31, 2023 | 135 | -43 | -24.16% | 135 | 0 |
| Dec 31, 2022 | 178 | -7 | -3.78% | 178 | 0 |
| Dec 31, 2021 | 185 | -11 | -5.61% | 185 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ImmuCell | 73 |
| Gain Therapeutics | 21 |
| RenovoRx | 17 |
| MAIA Biotechnology | 13 |
| Atara Biotherapeutics | 10 |
| Alterity Therapeutics | 9 |
| Dogwood Therapeutics | 8 |
| Rallybio | 7 |
GOSS News
- 10 days ago - Gossamer Bio announces upt to $250M structured private placement - TheFly
- 10 days ago - Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval - Business Wire
- 15 days ago - Gossamer Bio reports Q2 EPS (8c), consensus (12c) - TheFly
- 15 days ago - Gossamer Bio price target lowered to $4 from $15 at Piper Sandler - TheFly
- 18 days ago - Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 18 days ago - Gossamer Bio Quarterly report: Q2 2026 - Filings
- 18 days ago - Gossamer Bio Earnings release: Q2 2026 - Filings
- 5 weeks ago - Gossamer Bio upgraded to Outperform from Market Perform at Leerink - TheFly